Refine by
Respiratory Patient Articles & Analysis
39 news found
It is a point-of-care device for assessing airway inflammation in patients with respiratory problems. With over 45 million NIOX® tests undertaken to date, the system is used by healthcare professionals around the world to help improve asthma care. ...
It can aid in the diagnosis of asthma and COPD and can also help identify patients who are at risk of progression to COPD. [1] The tremoflo® C-100 assesses respiratory function through simple tidal breathing and can be a valuable tool when compiling a detailed picture of respiratory function. It is particularly useful in enabling the very ...
Vitalograph, a global leader in the development and production of respiratory diagnostic solutions and clinical trial services, has launched the Vitalograph tremoflo® C-100 at this year’s ATS International Conference, taking place in Washington. ...
(NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of ...
(NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today ...
(NASDAQ: XAIR) a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today ...
(NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today ...
(NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today ...
“Our initial focus will be on the treatment of lower respiratory tract infections, for which there remains a significant unmet need. Our differentiated device technology platform has the potential to simplify the delivery of higher efficiency inhalation drug products, making effective therapies available for patients with compromised lung function.” ...
There are over 250 million people who suffer from lower respiratory tract infections (LTRI) every year and it is the 5th leading cause of death globally. The COVID-19 pandemic has highlighted the urgency for effective respiratory therapies. Inhaled anti-infectives dramatically improve the targeting of therapies to the site of respiratory ...
The initial targeted indications include: Post-operative Respiratory Depression. Respiratory depression is common in patients recovering from surgery and anesthesia. ...
Oxygen is a life-saving therapeutic gas, which is often used to treat patients with severe pneumonia and other respiratory diseases. Oxygen generator is an electric medical equipment. It first inhales air, removes nitrogen, then generates a continuous oxygen source, and delivers concentrated oxygen to patients who need ...
These analyses included patients ≥65 years old, those with co-morbidities associated with worse COVID-19 outcomes, and those who, at baseline, despite receiving low flow oxygen, had clinical signs of compromised respiratory function (defined as oxygen saturation of ≤ 92% or respiratory rate ≥ 21 breaths/min). These analyses showed ...
“With this technology, we can take a step forward in diagnosis and the allocation of different treatments in patients with chronic, severe respiratory failure,” De Backer summarizes. ...
ByFluidda
Etienne Jornod was Executive Chairman of the Galenica and Vifor Pharma Group, delivering 25 consecutive double-digit net profit growth, supporting millions of patients, and creating thousands of jobs. On 30 September 2020, he personally acquired OM Pharma together with entrepreneurs, aiming to create a unique biopharmaceutical company based on bacteria lysates expertise. OM ...
The bronchus regenerated, much as in the esophagus, first forming a tube and later developing into a bronchus with a functional lining known as the respiratory epithelium. The respiratory epithelium was seen in about two months in the pig. This respiratory epithelium is essential to the avoidance of infections such as pneumonia. ...
Approximately 80 percent of patients were non-ambulant, and all patients were on a stable regimen of steroids. ...
Funding Will Support Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Respiratory Infections in CF Patients CF Foundation to Invest up to $5 Million in BiomX Common Stock Data Readouts from Phase 1b/2a CF Trial of BX004 Expected in 2022 BiomX Inc. ...
ByBiomX
(VIDA) is further removing friction in respiratory clinical trials with the introduction of a new AI-powered portal. ...
Caroline Baxter, MD, is a Consultant Respiratory Physician at Manchester NHS Foundation Trust in the United Kingdom. ...